Clinical Trial

HER-2 B Cell Peptide Vaccine

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-05-10; most recent amendment 2025-08-19.
Status change: Not Yet Recruiting → Recruiting 2024-12-19
Trial Details
NCT Number NCT06414733
Lead Sponsor Pravin T.P Kaumaya
Conditions Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoma, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, EGFR Overexpression
Enrollment 42 participants
Start Date 2025-01-17
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-24